ArticleTropical medicine and health2025
Gram-negative bacterial bloodstream infections in cancer patients: a study of epidemiological trends and antibiotic susceptibility.
Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Extensively drug-resistant ESBL-producing enterobacterales and coexisting antimicrobial resistance genes are associated with mortality in critically ill patients with cancer.Scientific reports · 2026Article
- Managing multidrug resistant Gram-negative bacteraemia in immunocompromised hosts.Current opinion in infectious diseases · 2026Review
- Selenium-Loaded Calcium Phosphate with Long-Term and Curative Dosage Drug Release for Post-Surgical Osteosarcoma Management and Osteogenesis.International journal of molecular sciences · 2026Article
- Article
- Early procalcitonin kinetics as an independent predictor of mortality in multi-drug resistant Klebsiella spp. bloodstream infections: a retrospective cohort study.BMC infectious diseases · 2026Observational
- Leveraging real-time genomic surveillance to combat infectious diseases and antimicrobial resistance in cancer patients.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe primary aim of this study was to determine the epidemiological characteristics of Gram-negative bloodstream infections (BSIs) and the susceptibility profiles of the causative microorganisms in hospitalized patients with hematological and oncological malignancies.
methodsThis retrospective observational study investigated Gram-negative BSIs in patients over the age of 18 with a diagnosis of malignancy admitted to the hematology and oncology departments of Ankara Bilkent City Hospital between June 1, 2019, and September 1, 2023. Demographic data, disease activation status (new diagnosis, remission and relapse/refractory disease), causative Gram-negative microorganisms, and antibiotic susceptibilities were recorded.
resultsA total of 435 patients with 569 Gram-negative bacteremia were included. The median age of the patients was 56 years (range: 18-90 years), and 60.7% were male. Among the BSI episodes, 11.1% were catheter related. The most common Gram-negative pathogens were E. coli (40.6%), Klebsiella spp. (28.8%), and Pseudomonas spp. (9.1%). Of all isolates, 47.7% were multidrug-resistant (MDR), and 26.7% produced extended-spectrum beta-lactamase (ESBL). The rates of ESBL resistance were 40.3% and 28.7% for E. coli and Klebsiella spp., respectively, whereas the carbapenem resistance rates were 9.1% and 27.4%, respectively. Meropenem susceptibility rates were 93.4% for E. coli, 79.1% for Klebsiella spp., and 72.9% for Pseudomonas spp. MDR was most frequent in Acinetobacter spp. (56.5%) and Klebsiella spp. (56.1%), with the highest carbapenem resistance in Acinetobacter spp. (52.2%).
conclusionThis study highlights the high prevalence of MDR Gram-negative pathogens, limiting options for effective empirical therapy. The elevated rates of ESBL production, and carbapenem resistance are concerning and underscore the need for strengthened antimicrobial stewardship, updated guidelines, and new treatment options for managing Gram-negative BSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.